Century Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Century Therapeutics, Inc. (IPSC) reported Deferred Income Tax Expense (Benefit) of -$73.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-12
- Century Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$73.00K, a 108.39% decline from fiscal 2024.
- Century Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $870.00K.
- Century Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$3.00K, a 160.00% decline from fiscal 2022.
- Century Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was $5.00K.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$73.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | $870.00K 10-K · filed 2026-03-12 | $869.00K 10-K · filed 2025-03-19 |
| 2023-12-31 | -$3.00K 10-K · filed 2025-03-19 | |
| 2022-12-31 | $5.00K 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |